Ahmad Sadr - Net Worth and Insider Trading

Ahmad Sadr Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Ahmad Sadr owns 1 companies in total, including Apellis Pharmaceuticals Inc (APLS) .

Click here to see the complete history of Ahmad Sadr’s form 4 insider trades.

Insider Ownership Summary of Ahmad Sadr

Ticker	Comapny	Transaction Date	Type of Owner
APLS	Apellis Pharmaceuticals Inc	2019-04-08	See Remarks

Ahmad Sadr Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Ahmad Sadr Ownership Network

Ownership Network List of Ahmad Sadr

No Data

Ownership Network Relation of Ahmad Sadr

Ahmad Sadr Owned Company Details

What does Apellis Pharmaceuticals Inc do?

Who are the key executives at Apellis Pharmaceuticals Inc?

Ahmad Sadr is the See Remarks of Apellis Pharmaceuticals Inc. Other key executives at Apellis Pharmaceuticals Inc include General Counsel David O. Watson , See Remarks James George Chopas , and Chief Operating Officer Pascal Deschatelets .

Apellis Pharmaceuticals Inc (APLS) Insider Trades Summary

Over the past 18 months, Ahmad Sadr made no insider transaction in Apellis Pharmaceuticals Inc (APLS). Other recent insider transactions involving Apellis Pharmaceuticals Inc (APLS) include a net sale of 284,688 shares made by Pascal Deschatelets , a net sale of 433,087 shares made by Cedric Francois , and a net sale of 33,060 shares made by Timothy Eugene Sullivan .

In summary, during the past 3 months, insiders sold 42,192 shares of Apellis Pharmaceuticals Inc (APLS) in total and bought 0 shares, with a net sale of 42,192 shares. During the past 18 months, 1,150,422 shares of Apellis Pharmaceuticals Inc (APLS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,150,422 shares.

Apellis Pharmaceuticals Inc (APLS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Apellis Pharmaceuticals Inc Insider Transactions

No Available Data

Ahmad Sadr Mailing Address

Above is the net worth, insider trading, and ownership report for Ahmad Sadr. You might contact Ahmad Sadr via mailing address: C/o Apellis Pharmaceuticals, Inc., 6400 Westwind Way, Suite A, Crestwood Ky 40014.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.